期刊文献+

替莫唑胺缓释剂胶质瘤间质内化疗的实验研究 被引量:5

Experimental study of interstitial chemotherapy against glioma with sustained-release temozolomide
下载PDF
导出
摘要 目的观察肿瘤间质内应用替莫唑胺缓释剂(P-TMZ)对人脑胶质瘤的抑瘤效应。方法先以MTT法测定P-TMZ对SHG-44胶质瘤细胞的抑瘤效应,加药96h后检测不同药物浓度在570nm处的OD值,计算其IC50;再将SHG-44细胞接种于NC系裸小鼠右腋皮下,待肿瘤生长至体积约100mm3时,将荷瘤鼠随机分为P-TMZ组、替莫唑胺(temozolomide,TMZ)组、卡莫斯汀(BCNU)组和不载药微球(P-0)组,然后将P-TMZ(500mg/kg)、TMZ(50mg/kg)、BCNU(40mg/kg)和P-0(500mg/kg)以DMEM培养液混悬至终体积150μl,经皮多点穿刺缓慢注入相应组肿瘤间质内,每周测量皮下肿瘤大小2次。结果P-TMZ、TMZ和BCNU对SHG-44胶质瘤细胞的体外抑瘤效果明显,三者的IC50均<10μg/ml;与P-0组比较,差异均具有统计学意义(P<0.01)。在体内抑瘤实验中,P-TMZ、BCNU、TMZ抑瘤率均明显高于P-0(P<0.01)。P-TMZ和BCNU的抑瘤效应优于TMZ组(P<0.05)。结论P-TMZ保留了TMZ的抑瘤活性,兼具高稳定性和长时程药物作用时间等药代动力学特征,为胶质瘤病人肿瘤残腔内间质化疗提供了新的治疗选择。 Objective To observe the anti-tumor effect of interstitial chemotherapy with sustained-release temozolomide (P-TMZ) against glioma. Methods Anti-tumor effect of P-TMZ in vitro on human glioma cell line SHG-44 was evaluated by MTT assay. OD570 value of drugs with series dilution was detected after 96 h. IC50 of each drug was calculated based on inhibition ratios. The SHG-44 cells were inoculated subcutaneously into the right axil of NC nude mice. When the size of xenograft tumor reached 100 mm3, tumor-bearin...
出处 《中国微侵袭神经外科杂志》 CAS 2008年第10期455-458,共4页 Chinese Journal of Minimally Invasive Neurosurgery
基金 国家自然科学基金资助项目(编号:30400457 30772241) 江苏省科技厅青年科技创新人才项目资助(编号:BK2007507)
关键词 神经胶质瘤 替莫唑胺 迟效制剂 药物疗法 glioma temozolomide delayed-action preparations drug therapy
  • 相关文献

参考文献12

二级参考文献31

  • 1[1]Zhu K-J,Jiang H-L,Du X-Y,et al.Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide)microspheres using a modified water-in-oil-in-water(w/o/w)emulsion solvent evaporation technique[J].J Microencapsul,2001,18:247.
  • 2[2]Wang J,Wang BM,Schwen deman SP.Characterization of the initial burst release of a model peptide from poly(d,l-lactide-co-glycolide)microspheres[J].J Control Release,2002,82:289.
  • 3[3]Takenaga M,Yamaguehi Y,Kitagawa A,et al.A novel sustained-release formulation of insulin with dramatic reduction ininitial rapid release[J].J Control Release,2002,79:81.
  • 4[4]Pamujula,S,Graves R A,Kishore,-V.Preparation and in vitro characterization of amifostine biodegradable microcapsules[J].Eur J Pharm Biopharm,2004,57:213.
  • 5[5]Filipovic Grcic,Crc,-V,Jalsenjak,I.Albumin-loaded PLA and PLGA microspheres:in vitro evaluation[J].Boll Chim Farm,1999,138:14.
  • 6[6]Ueda,M;Iwara,A;Kreuter J.Influence of the preparation methods on the drug release behaviour of loperamide-loaded nanoparticles[J].J Microeneapsul,1998,15:361.
  • 7[7]Bridges,J F;Critchlow M;Iring M P.Radiolabeling,stability,and body distribution in rats,of low molecular weight polylactide homopolymer and polylactide-polyethyleneglycol copolymer[J].Biomaterials,2002,21:199.
  • 8[8]Le-Corre,P Rytting,J H,Gajan V.In vitro controlled release kinetics of local anaesthetics from poly(D,L-lactide)and poly(lactide-co-glycolide)micrespheres[J].J Microencapsul,1997,14:243.
  • 9[9]Wang FJ,Wang CH.Sustained release of etanidazole from spray dried microspheres prepared by non-halo-genatedsolvents[J].J Control Release,2002,81:263.
  • 10[10]Faisant N,Siepmann J,Benoit JP.PLGA-based micreparticles:elucidation of mechanisms and a new,simple mathematical model quantifying drug release[J].Eur J Pharm Sci,1002,15:355.

共引文献32

同被引文献40

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部